



Model List of Essential Medicines



BCG vaccine [General information](#)

Section

Immunologicals > Vaccines

- All vaccines should comply with the WHO requirements for biological substances.

Indications

[Need for immunization against tuberculosis](#)



Japanese encephalitis vaccine [General information](#)

Section

Immunologicals > Vaccines

- All vaccines should comply with the WHO requirements for biological substances.

Indications

[Need for immunization against certain single viral diseases](#)



Adalimumab [General information](#)

Section

Immunomodulators for non-malignant disease

- Parenteral > General injections > SC: 40 mg per 0.8 mL; 40 mg per 0.4 mL; 10 mg per 0.2 mL; 20 mg per 0.4 mL

Indications

[Axial spondyloarthritis Crohn disease site Rheumatoid arthritis](#)

Section

Medicines for juvenile joint diseases

- Parenteral > General injections > SC: 40 mg per 0.8 mL; 40 mg per 0.4 mL; 10 mg per 0.2 mL; 20 mg per 0.4 mL

Indications

[Juvenile idiopathic arthritis](#)



Ansuvimab [General information](#)

Section

Medicines for Ebola virus disease

- Parenteral > General injections > IV: 400 mg powder for injection

Indications

[Ebola virus disease](#)



Anti-D immunoglobulin [General information](#)

Section

Human immunoglobulins

- Parenteral > General injections > IV: 250 µg in single-dose vial
- Parenteral > General injections > IM: 250 µg in single-dose vial

Indications

[Maternal care for red cell antibodies Rh incompatibility reaction](#)



Anti-rabies immunoglobulin [General information](#)

Section

Human immunoglobulins

- Parenteral > General injections > IM: 150 IU per mL in vial
- Parenteral > Locoregional injections > Other: 150 IU per mL in vial

Indications

[Rabies](#)



Anti-rabies virus monoclonal antibodies [General information](#)

Section

Immunologicals > Sera, immunoglobulins and monoclonal antibodies

- Parenteral > Locoregional injections > Intradermal: 40 IU per mL in 1.25 mL vial (human); 40 IU per mL in 2.5 mL vial (human); 100 IU per mL in 2.5 mL vial (human); 300 IU per mL in 10 mL vial (murine); 600 IU per mL in 1 mL vial (murine); 600 IU per mL in 2.5 mL vial (murine); 600 IU per mL in 5 mL vial (murine)

Indications

[Rabies](#)



Anti-tetanus immunoglobulin [General information](#)

Section

Human immunoglobulins

- Parenteral > General injections > IM: 500 IU in vial

Indications

[Tetanus](#)



Antivenom immunoglobulin [General information](#)

Section

Immunologicals > Sera, immunoglobulins and monoclonal antibodies

- Parenteral > General injections > IV:

Indications

[Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified](#)



Asparaginase [General information](#)

Section

Cytotoxic medicines

- Powder for injection: 10 000 IU in vial.
- Parenteral > General injections > unspecified: 10000 IU in vial powder for injection

Indications

[Unspecified malignant neoplasms of ill-defined or unspecified sites Lymphoid leukaemia, not elsewhere classified](#)



Atezolizumab [General information](#)

Section

Immunomodulators

- Parenteral > General injections > IV: 840 mg per 14 mL in vial concentrate for solution for infusion; 1200 mg per 20 mL in vial concentrate for solution for infusion

Indications

Therapeutic equivalent to [pembrolizumab](#) for [Other specified malignant neoplasms of bronchus or lung](#)

Therapeutic equivalent to [pembrolizumab](#) for [Adenocarcinoma of stomach Hepatocellular carcinoma of liver](#)



Atoltivimab + maftivimab + odesivimab [General information](#)

Section

Medicines for Ebola virus disease

- Parenteral > General injections > IV: 241.7 mg + 241.7 mg + 241.7 mg in 14.5 mL vial

Indications

[Ebola virus disease](#)



Axicabtagene ciloleucel [General information](#)

Section

Antineoplastics and supportive medicines

- Cell suspension for infusion: 2×10^6 anti-CD19 CAR-positive viable T-cells per kg of body weight.

Indications

[Diffuse large B-cell lymphomas](#)



Beractant [General information](#)

Section

Medicines administered to the neonate [c]

- Respiratory > Suspension: 25 mg per mL for intratracheal instillation

Indications

[Respiratory distress syndrome of newborn](#)



Bevacizumab [General information](#)

Section

Ophthalmological preparations > Anti-vascular endothelial growth factor (VEGF) preparations

- Parenteral > Locoregional injections > Intravitreal: 25 mg per mL

Indications

[Age related macular degeneration](#)

Section

Immunomodulators

- Parenteral > General injections > IV: 25 mg per mL in 4 mL vial concentrate for solution for infusion; 25 mg per mL in 16 mL vial concentrate for solution for infusion

Indications

[Hepatocellular carcinoma of liver](#)



Cemiplimab [General information](#)

Section

Immunomodulators

- Parenteral > General injections > IV: 50 mg per mL in 7 mL vial concentrate for solution for infusion

Indications

Therapeutic equivalent to [pembrolizumab](#) for [Other specified malignant neoplasms of bronchus or lung](#)

Therapeutic equivalent to [pembrolizumab](#) for [Adenocarcinoma of stomach](#)



Certolizumab pegol [General information](#)

Section

Immunomodulators for non-malignant disease

Indications

Therapeutic equivalent to [adalimumab](#) for [Axial spondyloarthritis](#). Therapeutic equivalent to [adalimumab](#) for [Crohn disease site](#). Therapeutic equivalent to [adalimumab](#) for [Rheumatoid arthritis](#)

Section

Medicines for juvenile joint diseases

Indications

Therapeutic equivalent to [adalimumab](#) for [Juvenile idiopathic arthritis](#)



Cholera vaccine [General information](#)

Section

Immunologicals > Vaccines

- All vaccines should comply with the WHO requirements for biological substances.

Indications

[Need for immunization against cholera alone](#)



Coagulation factor IX complex [General information](#)

Section

Coagulation factors

Indications

Therapeutic equivalent to [coagulation factor IX, plasma-derived](#) for [Coagulation defects, purpura or other haemorrhagic or related conditions](#) Therapeutic equivalent to [coagulation factor IX, plasma-derived](#) for [Haemophilia B](#)

Coagulation factor IX, plasma-derived [General information](#)

Section

Coagulation factors

- Parenteral > General injections > IV: 500 IU in vial powder for injection; 1000 IU in vial powder for injection

Indications

[Coagulation defects, purpura or other haemorrhagic or related conditions](#) [Haemophilia B](#)

Coagulation factor VIII, plasma-derived [General information](#)

Section

Coagulation factors

- Parenteral > General injections > IV: 250 IU in vial powder for injection; 500 IU in vial powder for injection; 1000 IU in vial powder for injection

Indications

[Haemophilia A](#)

Cryoprecipitate (native) [General information](#)

Section

Blood and blood components

Indications

Therapeutic equivalent to [cryoprecipitate \(pathogen-reduced\)](#) for [Coagulation defects, purpura or other haemorrhagic or related conditions](#) Therapeutic equivalent to [cryoprecipitate \(pathogen-reduced\)](#) for [Obstetric haemorrhage](#) Therapeutic equivalent to [cryoprecipitate \(pathogen-reduced\)](#) for [Haemophilia A](#) Therapeutic equivalent to [cryoprecipitate \(pathogen-reduced\)](#) for [Von Willebrand disease](#)

Cryoprecipitate (pathogen-reduced) [General information](#)

Section

Blood and blood components

- Injection: frozen liquid in bag or lyophilized powder in vial containing:
 - > 50 IU Factor VIII
 - > 100 IU vWF
 - > 140 mg clottable fibrinogen per unit

Indications

[Coagulation defects, purpura or other haemorrhagic or related conditions](#) [Obstetric haemorrhage](#) [Haemophilia A](#) [Von Willebrand disease](#)

Dalteparin [General information](#)

Section

Medicines affecting coagulation

Indications

Therapeutic equivalent to [enoxaparin](#) for [Venous thromboembolism](#) Therapeutic equivalent to [enoxaparin](#) for [Acute ischaemic heart disease](#)

Darbepoetin alfa [General information](#)

Section

Antianaemia medicines

Indications

Therapeutic equivalent to [erythropoiesis-stimulating agents](#) for [Anaemia due to chronic disease](#)

Section

Supportive medicines

Indications

Therapeutic equivalent to [erythropoiesis-stimulating agents](#) for [Drug-induced aplastic anaemia](#)

Dengue vaccine [General information](#)

Section

Immunologicals > Vaccines

- All vaccines should comply with the WHO requirements for biological substances.

Indications

[Need for immunization against certain single viral diseases](#)

Diphtheria antitoxin [General information](#)

Section

Immunologicals > Sera, immunoglobulins and monoclonal antibodies

- Parenteral > General injections > IM: 10000 IU in vial; 20000 IU in vial

Indications

[Need for immunization against diphtheria alone](#)

Diphtheria vaccine [General information](#)

Section

Immunologicals > Vaccines

- All vaccines should comply with the WHO requirements for biological substances.

Indications

[Need for immunization against diphtheria alone](#)

Dostarlimab [General information](#)

Section

Immunomodulators

- Parenteral > General injections > IV: 50 mg per mL in 10 mL vial concentrate for solution for infusion

Indications

[Other specified malignant neoplasms of corpus uteri](#)

Dulaglutide [General information](#)

Section

Hypoglycaemic agents

Indications

Therapeutic equivalent to [semaglutide](#) for [Type 2 diabetes mellitus](#)

Durvalumab [General information](#)

Section

Immunomodulators

- Parenteral > General injections > IV: 50 mg per mL in 2.4 mL vial concentrate solution for infusion; 50 mg per mL in 10 mL vial concentrate solution for infusion

Indications

[Hepatocellular carcinoma of liver](#) [Malignant neoplasms of biliary tract, distal bile duct](#) [Malignant neoplasm of intrahepatic bile ducts](#) [Malignant neoplasms of gallbladder](#) [Malignant neoplasms of proximal biliary tract, cystic duct](#)

Emicizumab [General information](#)

Section

Medicines affecting coagulation

- Parenteral > General injections > SC: 12 mg per 0.4 mL in vial; 30 mg per mL in mL vial; 60 mg per 0.4 mL in vial; 105 mg per 0.7 mL in vial; 150 mg per mL in vial; 300 mg per 2 mL in vial

Indications

[Haemophilia A](#)

Enoxaparin [General information](#)

Section

Medicines affecting coagulation

- Parenteral > General injections > SC: 20 mg per 0.2 mL in prefilled syringe; 40 mg per 0.4 mL in prefilled syringe; 60 mg per 0.6 mL in prefilled syringe; 80 mg per 0.8 mL in prefilled syringe; 100 mg per 1 mL in prefilled syringe; 120 mg per 0.8 mL in prefilled syringe; 150 mg per 1 mL in prefilled syringe; 150 mg per 1 mL in ampoule; 20 mg per 0.2 mL in ampoule; 40 mg per 0.4 mL in ampoule; 60 mg per 0.6 mL in ampoule; 80 mg per 0.8 mL in ampoule; 100 mg per 1 mL in ampoule; 120 mg per 0.8 mL in ampoule

Indications

[Venous thromboembolism](#) [Acute ischaemic heart disease](#)

Epoetin alfa [General information](#)

Section

Antianaemia medicines

Indications

Therapeutic equivalent to [erythropoiesis-stimulating agents](#) for [Anaemia due to chronic disease](#)

Section

Supportive medicines

Indications

Therapeutic equivalent to [erythropoiesis-stimulating agents](#) for [Drug-induced aplastic anaemia](#)

Epoetin beta [General information](#)

Section

Antianaemia medicines

Indications

Therapeutic equivalent to [erythropoiesis-stimulating agents](#) for [Anaemia due to chronic disease](#)

Section

Supportive medicines

Indications

Therapeutic equivalent to [erythropoiesis-stimulating agents](#) for [Drug-induced aplastic anaemia](#)

Epoetin theta [General information](#)

Section

Antianaemia medicines

Indications

Therapeutic equivalent to [erythropoiesis-stimulating agents](#) for [Anaemia due to chronic disease](#)

Eptinezumab [General information](#)

Section

Medicines for migraine prophylaxis

Indications

Therapeutic equivalent to [fremanezumab](#) for [Chronic migraine](#)

Equine rabies immunoglobulin [General information](#)

Section

Immunologicals > Sera, immunoglobulins and monoclonal antibodies

- Parenteral > Locoregional injections > Intradermal: 150 IU per mL in vial; 200 IU per mL in vial; 300 IU per mL in vial; 400 IU per mL in vial

Indications

[Rabies](#)

Erenumab [General information](#)

Section

Medicines for migraine prophylaxis

Indications

Therapeutic equivalent to [fremanezumab](#) for [Chronic migraine](#)

Erythropoiesis-stimulating agents [General information](#)

Section

Antianaemia medicines

- Parenteral > General injections > unspecified: 1000 IU per 0.5 mL pre-filled syringe; 2000 IU per 0.5 mL pre-filled syringe; 3000 IU per 0.3 mL pre-filled syringe; 4000 IU per 0.4 mL pre-filled syringe; 5000 IU per 0.5 mL pre-filled syringe; 6000 IU per 0.6 mL pre-filled syringe; 8000 IU per 0.8 mL pre-filled syringe; 10000 IU per 1 mL pre-filled syringe; 20000 IU per 0.5 mL pre-filled syringe; 40000 IU per 1 mL pre-filled syringe

Indications

[Anaemia due to chronic disease](#)

Section

Supportive medicines

- Parenteral > General injections > unspecified: 2000 IU per mL in vial (single-dose); 3000 IU per mL in vial

(single-dose); 4000 IU per mL in vial (single-dose); 10000 IU per mL in vial (single-dose); 40000 IU per mL in vial (single-dose); 20000 IU per mL in vial (multiple-dose); 20000 IU per 2 mL in vial (multiple-dose)

Indications

[Drug-induced aplastic anaemia](#)

Etanercept [General information](#)

Section

Immunomodulators for non-malignant disease

Indications

Therapeutic equivalent to [adalimumab](#) for [Axial spondyloarthritis](#) Therapeutic equivalent to [adalimumab](#) for [Crohn disease site](#) Therapeutic equivalent to [adalimumab](#) for [Rheumatoid arthritis](#)

Section

Medicines for juvenile joint diseases

Indications

Therapeutic equivalent to [adalimumab](#) for [Juvenile idiopathic arthritis](#)

Filgrastim [General information](#)

Section

Immunomodulators

- Parenteral > General injections > SC: 120 µg per 0.2 mL in prefilled syringe; 300 µg per 0.5 mL in prefilled syringe; 480 µg per 0.8 mL in prefilled syringe; 300 µg per mL in 1 mL vial; 480 µg per 1.6 mL in 1.6 mL vial

Indications

[Acquired neutropaenia](#)

Fremanezumab [General information](#)

Section

Medicines for migraine prophylaxis

- Parenteral > General injections > SC: 225 mg per 1.5 mL in pre-filled syringe

Indications

[Chronic migraine](#)

Fresh-frozen plasma [General information](#)

Section

Blood and blood components

- Parenteral > General injections > IV:

Indications

[Blood transfusion without reported diagnosis](#)

Galcanezumab [General information](#)

Section

Medicines for migraine prophylaxis

Indications

Therapeutic equivalent to [fremanezumab](#) for [Chronic migraine](#)

Golimumab [General information](#)

Section

Immunomodulators for non-malignant disease

Indications

Therapeutic equivalent to [adalimumab](#) for [Axial spondyloarthritis](#) Therapeutic equivalent to [adalimumab](#) for [Crohn disease site](#) Therapeutic equivalent to [adalimumab](#) for [Rheumatoid arthritis](#)

Section

Medicines for juvenile joint diseases

Indications

Therapeutic equivalent to [adalimumab](#) for [Juvenile idiopathic arthritis](#)

Haemophilus influenzae type b vaccine [General information](#)

Section

Immunologicals > Vaccines

- All vaccines should comply with the WHO requirements for biological substances.

Indications

[Need for immunization against single bacterial diseases](#)

Hepatitis A vaccine [General information](#)

Section

Immunologicals > Vaccines

- All vaccines should comply with the WHO requirements for biological substances.

Indications

[Need for immunization against viral hepatitis](#)

Hepatitis B vaccine [General information](#)

Section

Immunologicals > Vaccines

- All vaccines should comply with the WHO requirements for biological substances.

Indications

[Need for immunization against viral hepatitis](#)

Human papilloma virus (HPV) vaccine [General information](#)

Section

Immunologicals > Vaccines

- All vaccines should comply with the WHO requirements for biological substances.

Indications

[Need for immunization against certain single viral diseases](#)

Infliximab [General information](#)

Section

Immunomodulators for non-malignant disease

Indications

Therapeutic equivalent to [adalimumab](#) for [Axial spondyloarthritis](#). Therapeutic equivalent to [adalimumab](#) for [Crohn disease site](#). Therapeutic equivalent to [adalimumab](#) for [Rheumatoid arthritis](#)

Section

Medicines for juvenile joint diseases

Indications

Therapeutic equivalent to [adalimumab](#) for [Juvenile idiopathic arthritis](#)

Influenza vaccine (seasonal) [General information](#)

Section

Immunologicals > Vaccines

- All vaccines should comply with the WHO requirements for biological substances.

Indications

[Need for immunization against influenza](#)

Insulin (analogue, long-acting) [General information](#)

Section

Insulins

- Parenteral > General injections > SC: 100 IU per mL in 3 mL cartridge solution; 100 IU per mL in 3 mL pre-filled pen solution; 100 IU per mL in 10 mL vial solution

Indications

[Type 2 diabetes mellitus](#) [Type 1 diabetes mellitus](#)

Insulin (human, intermediate-acting) [General information](#)

Section

Insulins

- Parenteral > General injections > SC: 40 IU per mL in 10 mL vial as compound insulin zinc suspension or isophane insulin; 100 IU per mL in 10 mL vial as compound insulin zinc suspension or isophane insulin; 100 IU per mL in 3 mL cartridge as compound insulin zinc suspension or isophane insulin; 100 IU per mL in 3 mL pre-filled pen as compound insulin zinc suspension or isophane insulin

Indications

[Type 2 diabetes mellitus](#) [Type 1 diabetes mellitus](#)

Insulin (human, short-acting) [General information](#)

Section

Insulins

- Parenteral > General injections > SC: 40 IU per mL in 10 mL vial solution; 100 IU per mL in 10 mL vial solution; 100 IU per mL in 3 mL cartridge solution; 100 IU per mL in 3 mL pre-filled pen solution

Indications

[Type 2 diabetes mellitus](#) [Type 1 diabetes mellitus](#)

Insulin degludec [General information](#)

Section

Insulins

Indications

Therapeutic equivalent to [insulin \(analogue, long-acting\)](#) for [Type 2 diabetes mellitus](#) Therapeutic equivalent to [insulin \(analogue, long-acting\)](#) for [Type 1 diabetes mellitus](#)

Insulin detemir [General information](#)

Section

Insulins

Indications

Therapeutic equivalent to [insulin \(analogue, long-acting\)](#) for [Type 2 diabetes mellitus](#) Therapeutic equivalent to [insulin \(analogue, long-acting\)](#) for [Type 1 diabetes mellitus](#)

Insulin glargine [General information](#)

Section

Insulins

Indications

Therapeutic equivalent to [insulin \(analogue, long-acting\)](#) for [Type 2 diabetes mellitus](#) Therapeutic equivalent to [insulin \(analogue, long-acting\)](#) for [Type 1 diabetes mellitus](#)

Ipilimumab [General information](#)

Section

Immunomodulators

- Parenteral > General injections > IV: 5 mg per mL in 10 mL vial concentrate for solution for infusion; 20 mg per mL in 40 mL vial concentrate for solution for infusion

Indications

[Other specified malignant neoplasms of bronchus or lung](#) [Renal cell carcinoma of kidney, except renal pelvis](#) [Squamous cell carcinoma of oesophagus](#) [Melanoma of skin](#)

Liraglutide [General information](#)

Section

Hypoglycaemic agents

Indications

Therapeutic equivalent to [semaglutide](#) for [Type 2 diabetes mellitus](#)

Lisocabtagene maraleucel [General information](#)

Section

Antineoplastics and supportive medicines

Indications

Therapeutic equivalent to [axicabtagene ciloleucel](#) for [Diffuse large B-cell lymphomas](#)

Measles vaccine [General information](#)

Section

Immunologicals > Vaccines

- All vaccines should comply with the WHO requirements for biological substances.

Indications

[Need for immunization against measles alone](#)



Meningococcal meningitis vaccine [General information](#)

Section

Immunologicals > Vaccines

- All vaccines should comply with the WHO requirements for biological substances.

Indications

[Need for immunization against single bacterial diseases](#)



Methoxy polyethylene glycol-epoetin beta [General information](#)

Section

Antianaemia medicines

Indications

Therapeutic equivalent to [erythropoiesis-stimulating agents](#) for [Anaemia due to chronic disease](#)



Mumps vaccine [General information](#)

Section

Immunologicals > Vaccines

- All vaccines should comply with the WHO requirements for biological substances.

Indications

[Need for immunization against mumps alone](#)



Nadroparin [General information](#)

Section

Medicines affecting coagulation

Indications

Therapeutic equivalent to [enoxaparin](#) for [Venous thromboembolism](#) Therapeutic equivalent to [enoxaparin](#) for [Acute ischaemic heart disease](#)



Nivolumab [General information](#)

Section

Immunomodulators

- Parenteral > General injections > IV: 10 mg per mL in 4 mL vial concentrate solution for infusion; 10 mg per mL in 10 mL vial concentrate solution for infusion; 10 mg per mL in 12 mL vial concentrate solution for infusion; 10 mg per mL in 24 mL vial concentrate solution for infusion
- Parenteral > General injections > IV: 10 mg per mL in 24 mL vial concentrate solution for infusion; 10 mg per mL in 4 mL vial concentrate solution for infusion; 10 mg per mL in 10 mL vial concentrate solution for infusion; 10 mg per mL in 12 mL vial concentrate solution for infusion

Indications

[Other specified malignant neoplasms of bronchus or lung](#) [Melanoma of skin](#) [Renal cell carcinoma of kidney, except renal pelvis](#) [Squamous cell carcinoma of oesophagus](#) [Adenocarcinoma of oesophagogastric junction](#) [Adenocarcinoma of stomach](#)



Normal immunoglobulin [General information](#)

Section

Human immunoglobulins

- Parenteral > General injections > IV: 5% protein solution; 10% protein solution
- Parenteral > General injections > IM: 16% protein solution
- Parenteral > General injections > SC: 15% protein solution; 16% protein solution

Indications

[Primary immunodeficiencies](#) [Mucocutaneous lymph node syndrome](#) [Langerhans cell histiocytosis](#)

Section

Medicines for Guillain-Barré syndrome

- Parenteral > General injections > IV: 5% protein solution; 10% protein solution

Indications

[Acute inflammatory demyelinating polyneuropathy](#)



Ocrelizumab [General information](#)

Section

Medicines for multiple sclerosis

- Parenteral > General injections > IV: 30 mg per mL in 10 vial concentrate for solution

Indications

[Multiple sclerosis](#)



Pegaspargase [General information](#)

Section

Cytotoxic medicines

- Parenteral > General injections > IV: 3750 units per 5 mL in vial; 3750 units in vial powder for injection

Indications

[Lymphoid leukaemia, not elsewhere classified](#)



Pegfilgrastim [General information](#)

Section

Immunomodulators

- Parenteral > General injections > SC: 6 mg per 0.6 mL in pre-filled syringe

Indications

[Acquired neutropaenia](#)



Pegylated interferon alfa (2a) [General information](#)

Section

Medicines for hepatitis C > Other antivirals for hepatitis C

- Parenteral > General injections > SC: 180 µg in vial; 180 µg in prefilled syringe

Indications

[Chronic hepatitis C](#)



Pegylated interferon alfa (2b) [General information](#)

Section

Medicines for hepatitis C > Other antivirals for hepatitis C

- Parenteral > General injections > SC: 80 µg in prefilled syringe; 100 µg in prefilled syringe

Indications

[Chronic hepatitis C](#)



Pembrolizumab [General information](#)

Section

Immunomodulators

- Parenteral > General injections > IV: 25 mg per mL in 4 mL vial
- Parenteral > General injections > IV: 25 mg per mL in 4 mL vial powder for injection
- Parenteral > General injections > IV: 25 mg per mL in 4 mL vial concentrate for solution for infusion

Indications

[Other specified malignant neoplasms of large intestine](#) [Other specified malignant neoplasms of bronchus or lung](#) [Adenocarcinoma of stomach](#) [Squamous cell carcinoma of hypopharynx and variants](#) [Squamous cell carcinoma of other or ill-defined sites in the lip, oral cavity or pharynx](#) [Squamous cell carcinoma of oropharynx](#) [Squamous cell carcinoma of nasopharynx](#) [Malignant neoplasms of oesophagogastric junction](#) [Renal cell carcinoma of kidney, except renal pelvis](#) [Carcinoma of breast, specialised type](#) [Squamous cell carcinoma of oesophagus](#) Therapeutic equivalent to [nivolumab](#) for [Melanoma of skin](#)



Pertussis vaccine [General information](#)

Section

Immunologicals > Vaccines

- All vaccines should comply with the WHO requirements for biological substances.

Indications

[Need for immunization against pertussis alone](#)



Platelets [General information](#)

Section

Blood and blood components

- Parenteral > General injections > IV:

Indications

[Blood transfusion without reported diagnosis](#)

Pneumococcal vaccine [General information](#)

Section

Immunologicals > Vaccines

- All vaccines should comply with the WHO requirements for biological substances.

Indications

[Need for immunization against single bacterial diseases](#)

Poliomyelitis vaccine [General information](#)

Section

Immunologicals > Vaccines

- All vaccines should comply with the WHO requirements for biological substances.

Indications

[Need for immunization against poliomyelitis](#)

Rabies vaccine [General information](#)

Section

Immunologicals > Vaccines

- All vaccines should comply with the WHO requirements for biological substances.

Indications

[Need for immunization against rabies](#)

Red blood cells [General information](#)

Section

Blood and blood components

- Parenteral > General injections > IV:

Indications

[Blood transfusion without reported diagnosis](#)

Rituximab [General information](#)

Section

Targeted therapies

- Parenteral > General injections > IV: 100 mg per 10 mL in 10 mL vial; 500 mg per 50 mL in 50 mL vial

Indications

[Follicular lymphoma Diffuse large B-cell lymphoma, not otherwise specified Chronic lymphocytic leukaemia or small lymphocytic lymphoma Burkitt lymphoma including Burkitt leukaemia](#)

Section

Medicines for multiple sclerosis

- Parenteral > General injections > IV: 500 mg per 50 mL in 50 mL vial

Indications

[Multiple sclerosis](#)

Rotavirus vaccine [General information](#)

Section

Immunologicals > Vaccines

- All vaccines should comply with the WHO requirements for biological substances.

Indications

[Need for immunization against certain single viral diseases](#)

Rubella vaccine [General information](#)

Section

Immunologicals > Vaccines

- All vaccines should comply with the WHO requirements for biological substances.

Indications

[Need for immunization against rubella alone](#)

Semaglutide [General information](#)

Section

Hypoglycaemic agents

- Parenteral > General injections > SC: 0.68 mg per mL; 1.34 mg per mL; 2.68 mg per mL

Indications

[Type 2 diabetes mellitus](#)

Tetanus vaccine [General information](#)

Section

Immunologicals > Vaccines

- All vaccines should comply with the WHO requirements for biological substances.

Indications

[Need for immunization against tetanus alone](#)

Tick-borne encephalitis vaccine [General information](#)

Section

Immunologicals > Vaccines

- All vaccines should comply with the WHO requirements for biological substances.

Indications

[Need for immunization against arthropod-borne viral encephalitis](#)

Tirzepatide [General information](#)

Section

Hypoglycaemic agents

Indications

Therapeutic equivalent to [semaglutide](#) for [Type 2 diabetes mellitus](#)

Tisagenlecleucel [General information](#)

Section

Antineoplastics and supportive medicines

Indications

Therapeutic equivalent to [axicabtagene ciloleucel](#) for [Diffuse large B-cell lymphomas](#)

Tislelizumab [General information](#)

Section

Immunomodulators

- Parenteral > General injections > IV: 100 mg per 10 mL concentrate for solution for infusion

Indications

[Other specified malignant neoplasms of bronchus or lung](#)

Toripalimab [General information](#)

Section

Immunomodulators

- Parenteral > General injections > IV: 240 mg per 6 mL in vial

Indications

[Malignant neoplasms of nasopharynx Squamous cell carcinoma of oesophagus](#)

Trastuzumab [General information](#)

Section

Targeted therapies

- Parenteral > General injections > IV: 60 mg in vial powder for injection; 150 mg in vial powder for injection; 440 mg in vial powder for injection

Indications

[Carcinoma of breast, specialised type](#)

Tremelimumab [General information](#)

Section

Immunomodulators

- Parenteral > General injections > IV: 20 mg per mL in 1.25 mL vial concentrate solution for infusion; 20 mg per mL in 15 mL vial concentrate solution for infusion

Indications

[Hepatocellular carcinoma of liver](#) [Other specified malignant neoplasms of bronchus or lung](#)



Typhoid vaccine [General information](#)

Section

Immunologicals > Vaccines

- All vaccines should comply with the WHO requirements for biological substances.

Indications

[Need for immunization against typhoid-paratyphoid alone](#)



Ustekinumab [General information](#)

Section

Dermatological medicines > Medicines affecting skin differentiation and proliferation

- Parenteral > General injections > SC: 45 mg per 0.5 mL in vial; 45 mg per 0.5 mL in pre-filled syringe; 45 mg per 0.5 mL in pre-filled pen; 90 mg per mL in pre-filled syringe; 90 mg per mL in pre-filled pen

Indications

[Psoriasis of unspecified type](#)



Varicella vaccine [General information](#)

Section

Immunologicals > Vaccines

- All vaccines should comply with the WHO requirements for biological substances.

Indications

[Need for immunization against certain single viral diseases](#)



Whole blood [General information](#)

Section

Blood and blood components

- Parenteral > General injections > IV:

Indications

[Blood transfusion without reported diagnosis](#)



Yellow fever vaccine [General information](#)

Section

Immunologicals > Vaccines

- All vaccines should comply with the WHO requirements for biological substances.

Indications

[Need for immunization against certain single viral diseases](#)